By Fineline Cube 
Panboron (Hainan) BNCT Hospital, a subsidiary of China Biotech Services Holdings Limited (HKG: 8037), officially signed a strategic cooperation agreement with OncoCare Cancer Centre HK on September 2, 2026. The two parties will jointly build a cross‑border oncology diagnosis and treatment collaboration mechanism, launching international medical cooperation for BNCT (Boron Neutron Capture Therapy).
Deal Milestone
| Item | Detail |
|---|---|
| Party A | Panboron (Hainan) BNCT Hospital — subsidiary of China Biotech Services Holdings (HKG: 8037) |
| Party B | OncoCare Cancer Centre HK |
| Agreement Type | Strategic cooperation agreement |
| Signing Date | 2 Sep 2026 |
| Scope | Cross‑border oncology diagnosis & treatment collaboration for BNCT |
| Location Advantage | Boao Lecheng International Medical Tourism Pilot Zone, Hainan |
Collaboration Framework — Full‑Chain Service Mechanism
The agreement establishes an “offshore evaluation + onshore treatment + offshore follow‑up” full‑chain service mechanism:
| Function | Responsible Party |
|---|---|
| Public science communication overseas | OncoCare Cancer Centre HK |
| Initial patient screening & evaluation | OncoCare Cancer Centre HK |
| Service coordination | OncoCare Cancer Centre HK |
| Post‑treatment offshore follow‑up management | OncoCare Cancer Centre HK |
| BNCT clinical treatment in China’s mainland | Panboron (Hainan) BNCT Hospital |
| Inpatient management | Panboron (Hainan) BNCT Hospital |
| Medical quality & safety | Panboron (Hainan) BNCT Hospital |
| Real‑time diagnosis & treatment progress sharing | Panboron (Hainan) BNCT Hospital |
Technology Profile — Boron Neutron Capture Therapy (BNCT)
- Modality: A form of precision radiotherapy operating at the cellular scale
- Mechanism: Targeted boron drugs accumulate boron‑10 within cancer cells; epithermal neutron beam irradiation then triggers a nuclear reaction that “point‑destroys” cancer cells while sparing surrounding normal tissues
- Equipment: Japan’s NeuCure neutron irradiation system
- Drug: Steboronine boron pharmaceutical
Approved Indications & Regulatory Pipeline
| Status | Indication |
|---|---|
| Approved (current) | Unresectable locally advanced or recurrent head and neck cancers — covering over ten subtypes, including nasopharyngeal, paranasal sinus, laryngeal, and oral cavity cancers |
| Expected by end of 2026 | High‑grade recurrent meningioma (additional indication, approval anticipated) |
Market Impact & Outlook
- Cross‑Border Medical Tourism Play: The partnership positions Panboron to capture international — particularly Greater China and Southeast Asian — patient inflow through Hainan’s Boao Lecheng International Medical Tourism Pilot Zone, China’s designated zone for early access to imported drugs and devices.
- Full‑Chain Model: The offshore/onshore division of labor mirrors the “evaluation–treatment–follow‑up” continuum increasingly adopted in cross‑border precision medicine, addressing a key barrier for overseas patients seeking treatment in China’s mainland.
- Indication Expansion: Approval of the high‑grade recurrent meningioma indication by year‑end would broaden BNCT’s addressable patient population beyond head and neck oncology into neuro‑oncology.
- Listed‑Company Exposure: For China Biotech Services Holdings (HKG: 8037), the agreement extends its CRO‑anchored business into clinical treatment services and international patient channels.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory approvals, cross‑border patient volumes, and commercialization of BNCT services. Actual results may differ due to risks including regulatory timelines, treatment capacity, market adoption, and competitive dynamics.-Fineline Info & Tech